Navigation Links
Savient Pharmaceuticals Reports First Quarter 2009 Financial Results
Date:5/6/2009

roval," said Paul Hamelin, President of Savient. "Early in the quarter, we combined the insights and strategic input of our panel of world class external experts with our internal understanding of this application resulting in our decision to file several key amendments which we believe strengthened and clarified the BLA. The FDA reviewed the amendments and determined that the additional information contained in the submissions constituted major amendments, accepted the amendments to the BLA and elected to extend the current review period and revised our PDUFA date to August 1, 2009. We also took aggressive steps to maintain a stable balance sheet by effectively controlling expenses during the period despite growing resource needs for manufacturing, the approval process and prelaunch preparation. In conjunction with being financially prudent, we successfully completed an important financing in the face of extraordinary market conditions, allowing us to strengthen our cash position as we approach our PDUFA action date. We believe the first quarter of 2009 has been an important transitionary quarter for the Company, resulting in significant progress achieved towards our commitment to bring KRYSTEXXA to the market to treat the disabling aspects of the treatment failure gout population."

Financial Results of Operations for the Three Months Ended March 31, 2009

Total revenues decreased $0.1 million, or 8%, to $1.1 million for the three months ended March 31, 2009, from $1.2 million for the three months ended March 31, 2008. The decrease was due to lower gross product sales of Oxandrin(R), our product that promotes weight gain following involuntary weight loss due to disease or medical condition, as a result of the continued impact of generic competition partially offset by lower provisions for product returns year over year. We expect that revenues from Oxandrin and our authorized generic product oxandrolone will de
'/>"/>

SOURCE Savient Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Savient Pharmaceuticals to Hold Third Quarter 2008 Financial Results Conference Call on Thursday, November 6, 2008
2. Savients Pegloticase Data in Treatment-Failure Gout Patients Presented at 72nd Annual Meeting of the American College of Rheumatology Conference
3. Savient Submits Biologics License Application (BLA) for pegloticase
4. Savient Pharmaceuticals Reports Third Quarter 2008 Financial Results
5. Savient Pharmaceuticals to Present at the Lazard Capital Markets 5th Annual Healthcare Conference on November 18th
6. Savient Announces Appointment of David Gionco as Chief Financial Officer
7. Savient Pharmaceuticals to Hold Fourth Quarter and Year-End 2008 Results Conference Call on Thursday, February 26, 2009
8. Savient Pharmaceuticals to Raise $31 Million Through Registered Direct Offering
9. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
10. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
11. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... September 30, 2014 The ... IACRN), a non-profit organization based in Pittsburgh, Pennsylvania, ... and Safety (ACRES), a Massachusetts non-profit charitable ... alliance agreement, setting the stage for multiple collaborative ... clinical research quality and safety through specialized nursing ...
(Date:9/29/2014)... Sept. 29, 2014 Research and Markets ... Market by Product & Services, End-User , Application - ... The global oligonucleotide synthesis market is ... million in 2014, growing at a CAGR of 9.8% ... is categorized on the basis of products and services, ...
(Date:9/29/2014)... 2014 According to ... Product (Modifying Enzymes, DNA Polymerase, Acetylase, Methyltransferase, ... Reagents), by Research Area (Developmental Biology, Oncology), ... 2019", published by MarketsandMarkets, provides a detailed ... current market trends, and strategies impacting the ...
(Date:9/29/2014)... , Sept. 29, 2014 /PRNewswire/ - SQI Diagnostics ... that develops and commercializes proprietary technologies and products for ... of Peter Winkley to Chairman of the ... .  Mr. Ricks will continue to serve as a ... leadership to the Company.  "We are ...
Breaking Biology Technology:IACRN and ACRES to Support Clinical Research Nurses 2IACRN and ACRES to Support Clinical Research Nurses 3Oligonucleotide Synthesis (Diagnostics, PCR, QPCR, Gene Synthesis, NGS, DNA, RNAi) Market - Global Forecast to 2019 2Oligonucleotide Synthesis (Diagnostics, PCR, QPCR, Gene Synthesis, NGS, DNA, RNAi) Market - Global Forecast to 2019 3Epigenetics Market Worth $783.17 Million by 2019 2Epigenetics Market Worth $783.17 Million by 2019 3Epigenetics Market Worth $783.17 Million by 2019 4SQI Diagnostics Announces New Chairman of Board of Directors 2
... By Julia Cino, PhD , ... Introduction , ... manipulate DNA to identify,excise, move and place genes into a variety of ... for many of these recombinant organisms is to produce,proteins. Since many proteins ...
... , ... , ... protocols for culturing cells in a BioFlo 110,benchtop fermentor/bioreactor system. ... control modules to enable growth of,a wide variety of cultures, including mammalian, ...
... , , ... This Application Report is part of a series documenting,culture growth in the ... well as mammalian,plant cells and insect cells., , ... , Pichia pastoris ...
Cached Biology Technology:High Yield Protein Production from Pichia pastoris Yeast: A Protocol for Benchtop Fermentation 2High Yield Protein Production from Pichia pastoris Yeast: A Protocol for Benchtop Fermentation 3High Yield Protein Production from Pichia pastoris Yeast: A Protocol for Benchtop Fermentation 4High Yield Protein Production from Pichia pastoris Yeast: A Protocol for Benchtop Fermentation 5High Yield Protein Production from Pichia pastoris Yeast: A Protocol for Benchtop Fermentation 6High Yield Protein Production from Pichia pastoris Yeast: A Protocol for Benchtop Fermentation 7High Yield Protein Production from Pichia pastoris Yeast: A Protocol for Benchtop Fermentation 8Hybridoma Cell Culture Application Using a BioFlo 110 Benchtop Bioreactor 2Hybridoma Cell Culture Application Using a BioFlo 110 Benchtop Bioreactor 3Hybridoma Cell Culture Application Using a BioFlo 110 Benchtop Bioreactor 4Hybridoma Cell Culture Application Using a BioFlo 110 Benchtop Bioreactor 5Hybridoma Cell Culture Application Using a BioFlo 110 Benchtop Bioreactor 6P. pastoris Fermentation using a BioFlo 110 Benchtop Fermentor 2P. pastoris Fermentation using a BioFlo 110 Benchtop Fermentor 3P. pastoris Fermentation using a BioFlo 110 Benchtop Fermentor 4P. pastoris Fermentation using a BioFlo 110 Benchtop Fermentor 5P. pastoris Fermentation using a BioFlo 110 Benchtop Fermentor 6P. pastoris Fermentation using a BioFlo 110 Benchtop Fermentor 7P. pastoris Fermentation using a BioFlo 110 Benchtop Fermentor 8
(Date:9/29/2014)... inaccessible or esoteric. Yet in the modern world, it ... lives and a decisive role in the discovery and ... , UC Santa Barbara,s Paul Atzberger, a professor in ... mechanical engineering, often works in areas where science and ... the Proceedings of the National Academy of Science ...
(Date:9/29/2014)... dinosaurs, gigantic reptilesdistant relatives of modern crocodilesruled the earth. ... it was thought they didn,t much interact. But a ... in the thigh of one of these ancient animals ... earth and planetary sciences lecturer, and her Virginia Tech ... marks in the thigh bones of an old reptile ...
(Date:9/29/2014)... , Canda, September 29, 2014 ... Such as UID Coupled with Increasing Security Concerns ... India is one ... witnessing increasing adoption of biometrics systems, majorly in ... e-drivers, NREGA, etc. Fingerprint modality based biometrics dominates ...
Breaking Biology News(10 mins):At the interface of math and science 2At the interface of math and science 3At the interface of math and science 4Tooth serves as evidence of 220 million-year-old attack 2India Biometrics Market to Surpass USD2.7 Billion by 2019, Finds TechSci Research Study 2India Biometrics Market to Surpass USD2.7 Billion by 2019, Finds TechSci Research Study 3
... by fungi, bacteria, and algae, is a common component of ... the medical field it,s approved by the FDA as ... surgery as a substance that opens the blood/brain barrier to ... Gazit and Daniel Segal of Tel Aviv University,s Department of ...
... controversial method of mining shale gas, is widespread across Pennsylvania, ... research in the Annals of the New York Academy ... pollution from toxic chemicals, the building of well pads and ... a great deal of controversy, largely because of its impact ...
... 116 million years ago triggered a similar marine ecosystem ... result of global warming, according to research published today ... experts from the universities of Newcastle, UK, Cologne, Frankfurt ... a crash in the marine ecosystem during the mid-Cretaceous ...
Cached Biology News:Artificial sweetener a potential treatment for Parkinson's disease 2Global cooling as significant as global warming 2
Taq DNA polymerase, 10,000U...
... - 5 units/µL ,• High specific activity ... Leaves an 'A' overhang ,• Processes ... very high activity in primer extension and ... quality of the enzyme, each lot has ...
... a versatile and easy-to use enzyme, with ... Taq DNA Polymerase is prepared from a ... the DNA polymerase I gene from Thermococcus ... 5'-3' DNA polymerase activity. Its inherent 3'-5' ...
A robust formulation of Taq Polymerase supplied with a 10X colored reaction buffer which allows Direct Gel-Loading...
Biology Products: